Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person UniProt:P30511-2 HLA-F
| Class:Id | ReferenceIsoform:8972434 |
|---|---|
| _chainChangeLog | signal peptide:1-21 added on Fri February 17 2017;chain:22-346 added on Fri February 17 2017 |
| _displayName | UniProt:P30511-2 HLA-F |
| _timestamp | 2024-11-03 19:41:15 |
| chain | signal peptide:1-21 chain:22-346 |
| checksum | D4782968A67E9B7D |
| comment | FUNCTION Non-classical major histocompatibility class Ib molecule postulated to play a role in immune surveillance, immune tolerance and inflammation. Functions in two forms, as a heterotrimeric complex with B2M/beta-2 microglobulin and a peptide (peptide-bound HLA-F-B2M) and as an open conformer (OC) devoid of peptide and B2M (peptide-free OC). In complex with B2M, presents non-canonical self-peptides carrying post-translational modifications, particularly phosphorylated self-peptides. Peptide-bound HLA-F-B2M acts as a ligand for LILRB1 inhibitory receptor, a major player in maternal-fetal tolerance. Peptide-free OC acts as a ligand for KIR3DS1 and KIR3DL2 receptors (PubMed:28636952). Upon interaction with activating KIR3DS1 receptor on NK cells, triggers NK cell degranulation and anti-viral cytokine production (PubMed:27455421). Through interaction with KIR3DL2 receptor, inhibits NK and T cell effector functions (PubMed:24018270). May interact with other MHC class I OCs to cross-present exogenous viral, tumor or minor histompatibility antigens to cytotoxic CD8+ T cells, triggering effector and memory responses (PubMed:23851683). May play a role in inflammatory responses in the peripheral nervous system. Through interaction with KIR3DL2, may protect motor neurons from astrocyte-induced toxicity (PubMed:26928464).SUBUNIT Forms a heterotrimer with B2M and a self-peptide (PubMed:28636952). Binds a diverse number of peptides ranging from 7 to more than 30 amino acids (PubMed:28636952). Peptide-bound HLA-F-B2M interacts with LILRB1 and LILRB2 but not with KIR3DS1 or KIR3DL2; this interaction is direct (PubMed:11169396, PubMed:28636952). The OC form interacts with KIR3DS1, KIR2DS4 and KIR3DL2; this interaction is direct (PubMed:24018270, PubMed:27455421, PubMed:28636952). Interacts with TAP1-TAP2 complex and CALR; this interaction is required for appropriate folding and peptide loading (PubMed:10605026, PubMed:11169396). Interacts with the coat protein complex II and 14-3-3 proteins; these interactions likely control the anterograde ER-to-Golgi transport of HLA-F (PubMed:16709803). HLA-F-B2M complex interacts with the heavy chain of other MHC class I molecules including HLA-A and HLA-E; this interaction may regulate the intracellular trafficking and the stability of peptide-free MHC class I OCs (PubMed:20483783).INTERACTION For cross-presentation transits from the cell surface through endosomal pathway to lysosomes, where the peptide is generated from internalized exogenous antigen.ALTERNATIVE PRODUCTS Expressed in resting B cells (at protein level). Expressed in secondary lymphoid organs rich in B and T cells such as the tonsils, spleen, and thymus (at protein level) (PubMed:10605026, PubMed:11169396). Expressed in the endothelial cells of the tonsils (PubMed:11169396). Expressed on activated lymphoid cells including B cells, NK cells, CD4+ T cells and memory T cells (at protein level) (PubMed:20865824, PubMed:27455421). Expressed in motor neurons of spinal cord (PubMed:26928464).DEVELOPMENTAL STAGE Expressed in fetal liver (at protein level) (PubMed:10605026). Expressed in placenta villous mesenchyme, cytotrophoblast, syncytiotrophoblast and invasive extravillous trophoblast (at protein level) (PubMed:28185362).INDUCTION Up-regulated in CD4+ T cells upon stimulation via TCR and upon HIV-1 infection.PTM N-glycosylated.SIMILARITY Belongs to the MHC class I family.SEQUENCE CAUTION Extended N-terminus. |
| created | [InstanceEdit:8964659] Weiser, JD |
| description | recommendedName: HLA class I histocompatibility antigen, alpha chain F alternativeName: CDA12 alternativeName: HLA F antigen alternativeName: fullName evidence="26"Leukocyte antigen F alternativeName: MHC class I antigen F |
| geneName | HLA-F HLA-5.4 HLAF |
| identifier | P30511 |
| isoformParent | |
| isSequenceChanged | FALSE |
| keyword | 3D-structure Alternative splicing Cell membrane Disulfide bond Endosome Glycoprotein Immunity Lysosome Membrane MHC I Proteomics identification Reference proteome Signal Transmembrane Transmembrane helix |
| modified | [InstanceEdit:8987656] Weiser, JD [InstanceEdit:9037114] Weiser, JD [InstanceEdit:9637257] Weiser, JD [InstanceEdit:9676415] Weiser, JD [InstanceEdit:9715482] Weiser, JD [InstanceEdit:9730071] Weiser, JD [InstanceEdit:9852000] Weiser, Joel, 2023-11-03 [InstanceEdit:9917590] Weiser, Joel, 2024-08-09 [InstanceEdit:9926675] Weiser, Joel, 2024-11-03 |
| name | HLA-F |
| referenceDatabase | [ReferenceDatabase:2] UniProt |
| referenceGene | [ReferenceDNASequence:8962173] ENSEMBL:ENSG00000204642 HLA-F [Homo sapiens] |
| secondaryIdentifier | HLAF_HUMAN Q5JQI8 Q5JQJ1 Q5SPT5 Q860R0 Q8MGQ1 Q8WLP5 Q95HC0 Q9TP68 |
| sequenceLength | 346 |
| species | [Species:48887] Homo sapiens |
| variantIdentifier | P30511-2 |
| [Change default viewing format] | |
No pathways have been reviewed or authored by UniProt:P30511-2 HLA-F (8972434)
